Elena Ridloff
Director/Board Member chez KRONOS BIO, INC.
Fortune : 18 152 $ au 31/03/2024
Profil
Mme Elena H. Ridloff, CFA, est directrice indépendante de Kymera Therapeutics, Inc. et de Kronos Bio, Inc. et directrice financière et vice-présidente exécutive d'ACADIA Pharmaceuticals, Inc. Elle siège au conseil d'administration de Kymera Therapeutics, Inc. et de Kronos Bio, Inc. Auparavant, Mme Ridloff a occupé les postes de vice-présidente des relations avec les investisseurs chez Alexion Pharmaceuticals, Inc, de directrice générale et membre de la direction chez BioVision, Inc, d'analyste principale chez Maverick Capital Ltd et d'analyste principale chez Paramount BioCapital Asset Management, Inc. Elle a obtenu son diplôme de premier cycle à l'Université de Pennsylvanie.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
KRONOS BIO INC
0,02% | 22/06/2023 | 13 963 ( 0,02% ) | 18 152 $ | 31/03/2024 |
15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Elena Ridloff
Sociétés | Poste | Début |
---|---|---|
KRONOS BIO, INC. | Director/Board Member | 15/09/2020 |
KYMERA THERAPEUTICS, INC. | Director/Board Member | 12/03/2021 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Director of Finance/CFO | 01/01/2021 |
Anciens postes connus de Elena Ridloff
Sociétés | Poste | Fin |
---|---|---|
ACADIA PHARMACEUTICALS INC. | Director of Finance/CFO | 10/09/2021 |
ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 01/03/2018 |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology BioVision, Inc. manufactures pharmaceutical products for apoptosis and cell signaling. It offers assay kits, antibodies, and recombinant proteins and enzymes. The company is headquartered in Milpitas, CA. | Chief Executive Officer | 01/04/2014 |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | Analyst-Equity | 01/01/2012 |
Paramount BioCapital Asset Management, Inc.
Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Founded in 1991 by Dr. Lindsay Rosenwald, Paramount BioCapital Asset Management, Inc. is a hedge fund manager located in New York City. The firm is a subsidiary of Paramount BioCapital, Inc. | Corporate Officer/Principal | 01/06/2005 |
Formation de Elena Ridloff
University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
ACADIA PHARMACEUTICALS INC. | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
KRONOS BIO, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Paramount BioCapital Asset Management, Inc.
Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Founded in 1991 by Dr. Lindsay Rosenwald, Paramount BioCapital Asset Management, Inc. is a hedge fund manager located in New York City. The firm is a subsidiary of Paramount BioCapital, Inc. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | Finance |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology BioVision, Inc. manufactures pharmaceutical products for apoptosis and cell signaling. It offers assay kits, antibodies, and recombinant proteins and enzymes. The company is headquartered in Milpitas, CA. | Health Technology |
Stealth BioTherapeutics, Inc.
Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Stealth BioTherapeutics Corp., Stealth BioTherapeutics, Inc. develops therapies to treat mitochondrial dysfunctions and age-related diseases. The private company is based in Newton, MA. The company was founded in 2007. Irene P. McCarthy has been the CEO of the company since 2009. | Health Technology |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |